Surrozen (SRZN) Interest & Investment Income (2020 - 2026)
Surrozen (SRZN) recorded quarterly Interest & Investment Income of $912000.0 in Q1 2026, up 15.74% quarter-over-quarter from $788000.0 in Q4 2025, and up 208.11% on a YoY basis from $296000.0 in Q1 2025.
Surrozen (SRZN) Interest & Investment Income (2020 - 2026) Analysis & Trends
Surrozen's Interest & Investment Income history runs 7 years deep, the most recent figure standing at $912000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 208.11% year-over-year to $912000.0; the TTM figure through Mar 2026 stood at $3.6 million (up 126.68% YoY), while the FY2025 annual figure was $3.0 million, up 78.38% from the prior year.
- Interest & Investment Income was $912000.0 for Q1 2026 at Surrozen, up from $788000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.0 million in Q2 2025 to a low of $49000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $514470.6 across 5 years, with a median of $490000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income soared 1314.29% in 2022, then slumped 34.8% in 2024.
- A 5-year view of Interest & Investment Income shows it stood at $474000.0 in 2022, then advanced by 7.38% to $509000.0 in 2023, then decreased by 23.97% to $387000.0 in 2024, then surged by 103.62% to $788000.0 in 2025, then climbed by 15.74% to $912000.0 in 2026.
- The last three Interest & Investment Income figures came in at $912000.0 (Q1 2026), $788000.0 (Q4 2025), and $911000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -14.79 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 912,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 912,000.00 |
| Dec 31, 2025 | 788,000.00 |
| Sep 30, 2025 | 911,000.00 |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 296,000.00 |
| Dec 31, 2024 | 387,000.00 |
| Sep 30, 2024 | 431,000.00 |
| Jun 30, 2024 | 490,000.00 |
| Mar 31, 2024 | 385,000.00 |
| Dec 31, 2023 | 509,000.00 |
| Sep 30, 2023 | 661,000.00 |
| Jun 30, 2023 | 623,000.00 |
| Mar 31, 2023 | 547,000.00 |
| Dec 31, 2022 | 474,000.00 |
| Sep 30, 2022 | 198,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Mar 31, 2022 | 49,000.00 |
| Dec 31, 2021 | 42,000.00 |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | 7,000.00 |